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Results based on a large and representative patient sample demonstrate that the cost 
of seasonal influenza episodes is substantial, especially when complications occur. 
Costs in children may be higher of what is actually reported.
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Objectives: Clostridium difficile is the leading cause of antibiotic associated infec-
tious nosocomial diarrhoea. C. difficile infection is a high-priority problem of public 
health in each country. The available literature of C. difficile infection’s disease bur-
den is limited. The authors aimed to identify the most important cost elements and 
quantify the cost of C. difficile infection in Hungary. MethOds: A retrospective chart 
review and experts interviews were done in a sample of 151 patients with C. difficile 
infection in 2011 in two Hungarian hospitals. In the chart review data on demographic, 
disease severity, therapy, the standard precautions and the infection related contact 
precautions were collected. Cost analysis was done from the service provider’s per-
spective. Results: In department of medicine the annual average cost of C. difficile 
infection was € 800 per patient, the annual total cost of a recurrent patient was € 1810, 
the annual additional cost of contact precautions was € 330 per patient, the annual 
average cost of an episode was € 570, the additional cost of contact precautions was 
€ 235 per episode. In intensive care unit the annual average cost of C. difficile infec-
tion was € 1810 per patient, the annual total cost of a recurrent patient was € 3680, 
the annual additional cost of contact precautions was € 470 per patient, the annual 
average cost of an episode was € 1070, the additional cost of contact precautions 
was € 330 per episode. The most notable cost elements in intensive care unit were 
the hygienic costs and nurse wages, in department of medicine were the hygenic 
costs. cOnclusiOns: The importance of C. difficile infection in public health and 
the associated disease burden are significant. The costs differed based on the length 
of isolation, and the type of the provider department. The available data in Hungary 
are limited, further studies in epidemiology and health economics are required.
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Objectives: This analysis was conducted to demonstrate potential downstream 
health care cost savings as a result of increasing vaccination rates for influenza 
in the United States. MethOds: An age-structured susceptible-exposed-infec-
tious-recovered (SEIR) compartmental model was constructed to model the course 
of influenza infection over the course of 1 year in the United States. A realistic 
age structure was incorporated using mixing rates between age groups from the 
European POLYMOD survey. The SEIR model was adapted to include another com-
partment for vaccination. A series of difference equations was used to model 
transitions to and from each compartment. Time-dependent vaccination rates 
were obtained using monthly estimates of vaccination rates obtained from the 
Centers for Disease Control and Prevention (CDC). Cost and health care utilization 
data were obtained from the existing literature, and included outpatient visits, 
hospitalization, and antiviral drug treatment. Costs were reported in 2013 U.S. 
dollars. Microsoft Excel 2011 was used to conduct the analysis. Results: Under 
a base case vaccination rate of 40 percent, an estimated 11 percent of individu-
als in the United States were projected to have symptoms of influenza infection. 
Health care costs attributable to influenza infection were estimated to be $13.6 
billion. Increasing vaccination rates to 50 percent decreased the percentage of 
symptomatic individuals to approximately 7 percent, resulting in downstream 
health care costs of $9.5 billion. Further increasing vaccination rates to 60 percent 
is projected to further reduce downstream health care costs to approximately $5.0 
billion. cOnclusiOns: This exploratory analysis demonstrates that significant 
health care cost savings can be realized by increasing vaccination rates for influ-
enza in the population.
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Objectives: Achieving optimal outcomes in the treatment of HIV requires high, 
sustained levels of medication adherence to antiretroviral therapy (ART). Across many 
conditions, suboptimal adherence has been shown to lead to poorer outcomes among 
patients. This study assessed the extent to which patients diagnosed with HIV are 
adherent with ART treatment guidelines and to illustrate associations between ART 
adherence and economic outcomes. MethOds: Commercially insured and Medicaid 
patients in the US from MarketScan claims databases with ≥ 2 claims containing an 
HIV/AIDS diagnosis code between June 1, 2006 and December 31, 2011 who received 
an ART prescription between June 1, 2007 and December 31, 2010 were selected for 
initial inclusion. For each patient, the first ART prescription received during that time 
defined the index date. Patients were ≥ 18 years old on their index date and had ≥ 12 
months of continuous health plan enrollment with drug benefits before and after 
their index date. Adherence was measured by patients’ proportion of days covered 
(PDC) with a complete ART regimen during the 12-month post-index date period; 
patients with PDC ≥ 80% were considered adherent. Multivariable models (i.e., general-
ized linear; Poisson) assessed the relationship between ART adherence and economic 
outcomes (i.e., costs; number of health care encounters), controlling for demographic 
and clinical characteristics. Results: A total of14,590 commercially insured patients 
met all inclusion criteria, and 59% were adherent; 5,744 Medicaid patients met all 
estimate total 4177 DALYs caused by TBE in 2011. cOnclusiOns: TBE burden is 
quite large in Russia, thus economic evaluation of preventive measures is essential 
in order to choose the most cost-effective options.
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Objectives: Chronic hepatitis C virus (HCV) infection is estimated to effect 
approximately 15 million persons in Europe. It is a prevalent cause of progres-
sive liver disease including cirrhosis and hepatocellular carcinoma (HCC) and 
nearly 90,000 deaths that occur annually in the European region are related to 
HCV infection. The objective of this study was to evaluate the direct health care 
costs of HCV infection in countries of the European Union. MethOds: ENTREZ 
PUBMED was searched systematically for studies published between 2008 and 2013 
that evaluated the health care costs of persons with HCV infection in countries 
of the European Union. Of the 110 studies identified only 3 contained overall 
health care costs. Cost data was extracted, inflation adjusted to 2013 costs and 
averaged. Results: Based on the included studies, the average annual health 
care cost for a person with chronic HCV infection is € 2,756 with mild disease, 
€ 6,258 with cirrhosis, and € 11,437 with HCC. An HCV-related liver transplanta-
tion is estimated to have an average cost of € 68,497. The reported annual health 
care costs of patients with chronic HCV infection vary widely, with annual costs 
ranging between € 340 and € 6,773 among those categorized as having chronic 
infection and/or mild disease and between € 34,834 and € 124,594 among those who 
have had a liver transplantation. cOnclusiOns: The majority of recent studies 
have investigated antiviral drug treatment costs; few have examined the overall 
health care costs associated with chronic HCV infection in Europe. Based upon the 
data available, chronic HCV infection is associated with a substantial health care 
burden even among those categorized as having mild disease. Further research is 
needed to better understand the costs of HCV infection to enable more relevant 
screening and treatment strategies, especially among those at high risk for devel-
oping severe liver disease.
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Objectives: Bordetella pertussisinfection is highly contagious and can progress 
to severe conditions, especially among young children and elderly. This study aims 
to describe hospitalization patterns and costs for pertussis in children in public 
hospitals in Brazil, from 2008 to 2011. MethOds: A retrospective analysis of Brazil 
public hospital admissions for pertussis was developed according to ICD-10 classi-
fication (A37: Pertussis) in children (aged ≤ 9 years), as reported in Brazilian Hospital 
Information System (SIH/DATASUS) database from January 2008 to December 2011. 
Costs represents federal reimbursement values for hospitalizations (includes medi-
cal procedures, exams, medications and taxes), presented in 2013 Brazilian Real 
(BRL). Results: A total of 3055 hospital admissions for pertussis during the four-
year period were identified. There was a downward trend in the first three years 
of the analysis, while the opposite occurred in the fourth year, with 2011 having 
the highest number of cases (907, 655, 394 and 1,099 for 2008, 2009, 2010, and 2011, 
respectively). Infants were the most affected, with those less than one year of age 
accounting for 91% (n = 2,779) of all pertussis admissions in the age group analyzed. 
In-hospital mortality rate was 13.9% for all cause in the period. Mean length of stay 
was 7.56 days. Total cost for the period was 3,754,877 BRL, which represents 94.9% 
of pertussis hospitalization costs for all ages (3,958,133 BRL). Mean cost per patient 
was 1,229 BRL. cOnclusiOns: The costs with pertussis hospitalizations in children 
can be substantial in Brazil, from the public health care perspective. Despite the 
existence of a National Immunization Program, the number of cases in children 
remains high. It is therefore important that decision makers reassess the prevention 
and treatment patterns of this disease.
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Objectives: To evaluate cost of children and adults diagnosed with seasonal 
influenza in Germany, filling a data gap of more than a decade. MethOds: This 
cost-of-illness study was conducted from payer and societal perspective based on 
a retrospective database analysis by using a longitudinal electronic medical records 
database (IMS® Disease Analyzer). Patients with influenza episodes (ICD-10 diagnosis 
J09-11) being observable 12 months before index date and 1 month afterwards were 
included. The selection window was May 2010 to April 2012 to cover two influenza sea-
sons. Published unit costs and tariffs for Germany in 2012 were used. Results: A total 
of 23,068 influenza episodes (19,446 patients) managed by primary care practitioners 
(PCP) and 7,295 episodes (5,988 patients) managed by pediatricians were eligible for 
analysis. Mean age of patients with at least one episode was 43 years (SD 20) in the PCP 
panel and 7 years (SD 4) in the pediatrician panel. Total average mean cost (SD) from 
societal perspective in adult patients was € 471 (576) and in children € 99 (140)/episode. 
In about 11% of the adult patients the total cost exceeds € 1,000/episode. This is primar-
ily due to the higher percentage of patients with complications (63%) compared to the 
entire PCP study cohort (38%). Workdays lost were the main cost driver (82%) in adult 
patients; more than 40% of patients missed between 2 and 6 days of work/episode. 
In children, the main cost driver was physician visits (66%). Complications increase 
the cost by three fold in children and two fold in adults (average mean cost (SD) for 
children: € 137 (144) vs. € 49 (33) and adults: € 622 (670) vs. € 377 (485)). cOnclusiOns: 
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transformed to common logarithms. Costs are stated in € (1€ = 25.5CZK). Results: 
A total 100 patients (about 10-15% of all HIV treated in the Czech Republic) were 
included. The mean age was 41.9 years (range 23-71), time since diagnosis 5.8 years 
(range 1-26), and period of assessment 30.5 months. Average total annual costs were 
highest for CD4+ <200 (22,905€ ; p<0.05) vs. CD4+ 200-499 (17,801€ ) and CD4+ >500 
(17,043€ ). HIV medication accounted for the majority of costs in all three subgroups 
(range 62% in CD4+ <200 to 88% in CD4+ >500). Patients with a disease duration of 
>10 years had highest annual costs of 22,841€ (p<0.05) compared to 15,783€ (dura-
tion 5-10 years) and 16,777€ (<5 years). HIV-medication accounted for the majority 
of costs here as well (from 70% to 88%; NS). In this analysis 17 % of costs in patients 
with disease duration of >10 years were due to hospitalization vs. 5 % in both other 
groups (NS). cOnclusiOns: Similarly to published literature, we found highest 
costs in patients with low CD4+ lymphocytes and longer disease duration.
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Objectives: Clostridium difficileinfection (CDI) is the leading cause of infectious 
diarrhoea in hospitalised patients. The majority of published burden of CDI stud-
ies refer to US or northern European populations. Knowledge of the burden of CDI 
on health care resource utilisation in Spain is limited. The aim of the study was to 
provide recent data on the burden of CDI in terms of hospital resources and costs 
and in particular attributable length of stay. MethOds: A retrospective study was 
carried at a leading teaching hospital in Madrid. Data refer to sequential cases of 
CDI during the year 2011. Data were extracted from patient records using a prede-
fined structured protocol. Hospital onset CDI cases were matched at a ratio of two 
non-infected patients for each case to adjust for confounding variables. Results: 
A total of 44 CDI cases were identified of whom 25 were health care-associated 
and hospital-onset. The mean duration of diarrhoea (days) was 10.12+7.98. Using 
median regression, the attributable length of stay (LOS) due to CDI was 9.98+2.21 
days. The average number of isolation days was 9.21+8.27. The majority of patients 
were treated with oral metronidazole. The first episode cure rate was 83.7%, 30-day 
and overall mortality were 18.6 and 25.6% respectively, attributable mortality was 
4.65%. A total of 9.3% of patients experienced a recurrence occurring within 2-8 
weeks within hospital stay. The cost attributable to an individual case of CDI would 
be 4,331 euros, of which over 90% is associated with hospital LOS. cOnclusiOns: 
Our results highlight the significant burden of CDI in a large Spanish hospital. These 
costs will only continue to rise as the incidence of CDI continues to increase. A major 
breakthrough in cost reduction of CDI would be an intervention or procedure that 
shortens hospital length of stay and/or reduces episode recurrence.
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Objectives: Decreased susceptibility to vancomycin has led to recommendations for 
increased serum concentration targets for some infections, which has been shown 
to increase the risk of nephrotoxicity (NT). The objective of this study was to deter-
mine if vancomycin-induced nephrotoxicity has a significant impact on cost from the 
hospital perspective or on length of stay. MethOds: A cost of illness study from the 
hospital perspective. We conducted a secondary analysis of a cohort of 398 randomly 
selected inpatients receiving vancomycin in a tertiary care hospital in Rochester, New 
York, USA. Total and variable costs were generated by hospital accountants using 
micro-costing methods. NT was defined as 0.5 or 50% or greater increase in serum 
creatinine from baseline. Generalized linear models with log link and gamma distribu-
tion and semi-log regression were used to model total and variable costs and length 
of stay, respectively. Cost estimates are reported in 2009 USD. Results: Forty-nine 
(12%) of patients had NT. The unadjusted median variable costs for patients with NT 
were higher than for patients without NT ($47,511 vs. $22,355, p< .0001). On multi-
variable analysis, variable costs were 18% greater for patients with NT compared to 
patients without, but this difference was not statistically significant. The median 
length of stay for patients with NT was two-fold greater than for patients without 
NT (22 vs. 11 days, unadjusted, p< .0001). After accounting for severity of illness 
and other factors, NT patients stayed on average 46% longer than non-nephrotoxic 
patients. cOnclusiOns: Patients with NT have significantly increased length of 
stay relative to patients without NT. Further research is needed to confirm whether 
increased length of stay has a meaningful impact on costs. As vancomycin suscep-
tibility continues to decrease, higher doses of vancomycin may lead to an increased 
incidence of NT and an increase in resource utilization among these patients.
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Objectives: The purpose of this study was to estimate the health care resource uti-
lization, more specifically resource utilization for management of the most common 
adverse events (AE) associated with current treatment of hepatitis C virus (HCV) infec-
tion, in a real life setting. MethOds: A retrospective study of the Quebec provincial 
drug reimbursement program (RAMQ) was conducted using a random sample of 
patients who filed at least one script for an HCV medication (pegylated-interferon and 
ribavirin (Peg-Riba) +/-boceprevir or telaprevir) between January 2007 and December 
2012. Data on medical (excluding nurse visits) and pharmaceutical services were 
extracted from the RAMQ database. We report health care resources used during 
HCV treatment including outpatient physician’s visits and procedures, emergency 
inclusion criteria, and 42% were adherent. After adjusting for confounders, ART adher-
ence was associated with 29% and 31% reductions in non-pharmacy costs (p< 0.0001)), 
67% and 80% increases in total pharmacy costs (p< 0.0001), 43% and 49% reductions 
in hospitalizations (p< 0.0001), and 41% and 26% reductions in emergency depart-
ment visits (p< 0.0001), among commercially insured and Medicaid patients, respec-
tively. cOnclusiOns: This study suggests that ART adherence among commercially 
insured and Medicaid HIV patients in the US may be suboptimal, and that adherence 
is associated with improved economic outcomes among these patients.
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Objectives: To perform a systematic literature review of economic evidence for 
genotype 1 hepatitis C virus (HCV) treatments. MethOds: Searches were per-
formed in MEDLINE, MEDLINE In-Process, EconLit, Embase, BIOSIS, and the Cochrane 
Library, to identify economic evaluations, cost/resource studies, and utility studies 
in patients with genotype 1 HCV. Searches were limited to articles published since 
2000. Additional searches were performed on the ISPOR conference and key Health 
Technology Assessment (HTA) websites. Results: The review identified 53 economic 
evaluations, 17 HTA documents, 57 cost/resource use studies, and 19 utility stud-
ies. The majority of economic evaluations were in interferon-containing regimens 
and were performed using lifetime horizon Markov models. Incremental cost-effec-
tiveness ratios ranged from $4,570.31 to $157,404.13, depending on patient severity, 
the treatment used and the duration of treatment. Boceprevir and telaprevir triple 
therapies were shown to be cost-effective compared with peginterferon and ribavirin 
alone. In the cost studies, total all-cause, annual costs for patients with HCV ranged 
from $3,236 to $85,081, depending on the patients’ disease status and whether they 
were currently receiving treatment. Indirect costs for HCV patients were reported less 
frequently, but they ranged from $1,424 to $10,316 per patient per year. Utilities for 
patients with HCV ranged from 0.24 for patients experiencing severe adverse events 
to 0.89 for patients in sustained virological response. Recent economic models tended 
to use utility data taken from previous models or HTA submissions. cOnclusiOns: 
Numerous recent cost-effectiveness studies are available for HCV; however, many 
of the economic evaluations are based on previous models. There is a particular 
scarcity of updated country-specific utility data. As more treatment options become 
available, and more robust models are developed, enhanced utility and cost studies 
may be needed.
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Objectives: Meningococcal disease (MD) is a rare, life-threatening infection most 
common in infants (age < 1 year), adolescents, and persons living in close quar-
ters. In this study, we documented trends in hospital costs, length of stay (LOS), 
and mortality associated with pediatric MD cases in the United States (US) from 
2000 to 2009. MethOds: Data for pediatric (age ≤ 20 years) MD-related hospitaliza-
tions (discharges with ICD-9-CM 036.xx) from the 2000, 2003, 2006, and 2009 HCUP 
Kids’ Inpatient Databases (KID) were retrospectively analyzed. Charges were con-
verted to costs using a 0.5 cost-to-charge ratio. Weighted, nationally representa-
tive estimates of costs per admission (in 2012 US dollars), LOS, and case fatality 
rates were descriptively analyzed for each year. Results: By year, total (weighted) 
numbers of pediatric MD-related hospitalizations in the US were: 2000 (N= 1,680), 
2003 (N= 1,089), 2006 (N= 745), 2009 (N= 581). Mean [SD] LOS for these hospitaliza-
tions was 8.4 [12.9] days in 2000, which decreased modestly to 7.7 [9.6] and 7.9 
[8.3] days in 2003 and 2006, respectively, before a substantial increase to 9.3 [13.9] 
days in 2009. Mean [SD] cost per admission fluctuated accordingly, increasing from 
$25,739 [$60,929] in 2000 to $33,530 [$62,499] in 2009. Case fatality rates, however, 
remained relatively unchanged during the period, declining slightly from 4.7% in 
2000 to 4.3% in 2009, although a noticeable spike occurred in 2003 when 5.8% of 
cases died. cOnclusiOns: MD in the US pediatric population is associated with 
high costs resulting from hospital stays that typical exceed 1 week. Our estimated 
case fatality rate (~5%), while high, is lower than the 10-15% fatality rate estimated 
by the US Centers for Disease Control, which includes estimates from all age groups 
combined (pediatrics and adults). In light of these findings, recent efforts to raise 
awareness of MD as a serious public health concern should be continued.
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Objectives: To assess direct medical costs of HIV patients, based on CD4+ lym-
phocyte count and duration since diagnosis in the Czech setting. MethOds: We 
analyzed retrospectively costs of HIV patients in a single center. The analyzed sam-
ple included patients with a disease history of 12 month and longer, who regularly 
visited the center. Resource use, derived from the hospital information system, 
included services delivered at the HIV center and other hospital wards. The ret-
rospective period covered up to 36 months; average annual costs were calculated. 
Resource use was analyzed separately for (a) groups of CD4+ count (<200; 200-499; 
≥ 500); (b) time since diagnosis (<5 years; 5-10 years; >10 years). For comparison, 
two-sided Student’s t-test was used; to achieve normal distribution, values were 
